Amlitelimab + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Eczema
Conditions
Eczema, Atopic Dermatitis
Trial Timeline
Dec 13, 2021 → Feb 21, 2024
NCT ID
NCT05131477About Amlitelimab + Placebo
Amlitelimab + Placebo is a phase 2 stage product being developed by Sanofi for Eczema. The current trial status is completed. This product is registered under clinical trial identifier NCT05131477. Target conditions include Eczema, Atopic Dermatitis.
What happened to similar drugs?
2 of 13 similar drugs in Eczema were approved
Approved (2) Terminated (2) Active (9)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06557772 | Phase 2 | Active |
| NCT06444451 | Phase 2 | Active |
| NCT06407934 | Phase 3 | Active |
| NCT06181435 | Phase 3 | Completed |
| NCT06130566 | Phase 3 | Completed |
| NCT06118099 | Phase 2 | Terminated |
| NCT06033833 | Phase 2 | Active |
| NCT05421598 | Phase 2 | Completed |
| NCT05131477 | Phase 2 | Completed |
Competing Products
20 competing products in Eczema